Therapy With Bispecific Antibody for EGFR Exon 20 Insertion–Mutated NSCLC

home / case-based-roundtable-series / therapy-with-bispecific-antibody-for-egfr-exon-20-insertion-mutated-nsclc

This roundtable series reviews the use of treatment targeting EGFR exon 20 insertion mutations in patients with locally advanced or metastatic non–small cell lung cancer, as discussed by participants at virtual live events.

Using and Sequencing EGFR Exon 20-Targeted Therapies for NSCLC

Using and Sequencing EGFR Exon 20-Targeted Therapies for NSCLC

Xiuning Le, MD, PhD
April 27th 2022

Xiuning Le, MD, PhD, discusses counseling patients on the use of amivantamab-vmjw and mobocertinib and the sequencing of these drugs for patients with non–small cell lung cancer and an EGFR exon 20 insertion.

Tsao Picks Second-Line Therapy for a Patient With EGFR Exon 20+ NSCLC

Tsao Picks Second-Line Therapy for a Patient With EGFR Exon 20+ NSCLC

Targeted Oncology Staff
May 18th 2022

During a live virtual event, Anne S. Tsao, MD, discussed the choice of targeted therapy for a patient with non–small cell lung cancer with an EGFR exon 20 insertion.

EGFR Therapies Fail to Benefit Patients With NSCLC and Exon 20 Insertions

EGFR Therapies Fail to Benefit Patients With NSCLC and Exon 20 Insertions

Joshua K. Sabari, MD
June 29th 2022

Joshua K. Sabari, MD, discusses the significance of EGFR exon 20 insertion mutations in patients with non–small cell lung cancer.

Identifying Second-Line Options for NSCLC With EGFR Exon 20 Insertions

Identifying Second-Line Options for NSCLC With EGFR Exon 20 Insertions

Targeted Oncology Staff
July 8th 2022

During a live virtual event, Christine Bestvina, MD, discussed the use of amivantamab and mobocertinib, 2 new targeted therapies for patients with non–small cell lung cancer and an EGFR exon 20 insertion.

Results of Amivantamab and Mobocertinib Trials Evaluated for Use in NSCLC

Results of Amivantamab and Mobocertinib Trials Evaluated for Use in NSCLC

Targeted Oncology Staff
August 3rd 2022

During a Targeted Oncology case-based roundtable event, Christine Bestvina, MD, discussed the outcomes of clinical trials of the EGFR exon 20-targeted agents amivantamab and mobocertinib with participants. This is the second of 2 articles based on this event.

Amivantamab Shows Strong Efficacy in NSCLC With EGFR Exon 20 Insertion

Amivantamab Shows Strong Efficacy in NSCLC With EGFR Exon 20 Insertion

Erminia Massarelli, MD
September 7th 2022

Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.